Statistical inference for cost-effectiveness ratio

被引:0
作者
Laska, EM
Meisner, M
Siegel, C
机构
[1] NYU,SCH MED,NEW YORK,NY
[2] NATHAN S KLINE INST PSYCHIAT RES,STAT SCI LAB,ORANGEBURG,NY 10962
[3] NATHAN S KLINE INST PSYCHIAT RES,HLTH SERV & EPIDEMIOL LAB,ORANGEBURG,NY 10962
关键词
cost-effectiveness ratios; confidence intervals; hypothesis tests; Bonferroni intervals; Fieller intervals; clinical trials;
D O I
10.1002/(SICI)1099-1050(199705)6:3<229::AID-HEC268>3.0.CO;2-M
中图分类号
F [经济];
学科分类号
02 ;
摘要
Methods for statistical inference for cost-effectiveness (C/E) ratios for individual treatments and for incremental cost-effectiveness (Delta C/Delta E) ratios when two treatments are compared are presented. In a lemma, we relate the relative magnitude of two C/E ratios to the Delta C/Delta E ratio. We describe a statistical procedure to test for dominance, or admissibility, that can be used to eliminate an inferior treatment. The one-sided Bonferroni's confidence interval procedure is generalized to the two-sided case. The method requires only that two confidence intervals be available, one for cost and one for effectiveness. We describe Fieller-based confidence intervals and show them to be shorter than Bonferroni intervals. When distribution assumptions hold and variance and covariance estimates are available, Fieller intervals are preferable. However, Bonferroni intervals can be applied in more diverse situations and are easier to calculate. A simple Bonferroni based technique, and a likelihood ratio statistic given by Siegel, Laska and Meisner, for testing the null hypothesis that the C/E ratios of two treatments are equal is presented. The approaches are applied to the data from a phase II clinical trial of a new treatment for sepsis considered previously by others. (C) 1997 by John Wiley & Sons, Ltd.
引用
收藏
页码:229 / 242
页数:14
相关论文
共 29 条
[1]  
Chaudhary MA, 1996, STAT MED, V15, P1447
[2]  
Drummond M, 1987, METHODS EC EVALUATIO
[3]  
Drummond M F, 1991, Int J Technol Assess Health Care, V7, P561
[4]  
DRUMMOND MF, 1992, HEALTH ECON, V2, P205
[5]  
Feller W., 1957, INTRO PROBABILITY TH, VI
[6]  
Fieller E. C., 1944, QUART J PHARM PHARMA, V17, P117
[7]  
FIELLER EC, 1954, J ROY STAT SOC B, V16, P175
[8]  
FIELLER EC, 1940, J R STAT SOC, V137, P1
[9]  
FINNEY DJ, 1978, STATISTICAL METHOD B
[10]   INITIAL EVALUATION OF HUMAN RECOMBINANT INTERLEUKIN-1 RECEPTOR ANTAGONIST IN THE TREATMENT OF SEPSIS SYNDROME - A RANDOMIZED, OPEN-LABEL, PLACEBO-CONTROLLED MULTICENTER TRIAL [J].
FISHER, CJ ;
SLOTMAN, GJ ;
OPAL, SM ;
PRIBBLE, JP ;
BONE, RC ;
EMMANUEL, G ;
NG, D ;
BLOEDOW, DC ;
CATALANO, MA ;
FRIEDMAN, B ;
MURE, A ;
SHAPIRO, E .
CRITICAL CARE MEDICINE, 1994, 22 (01) :12-21